Myasthenia gravis
RSS feedThe MG-ADL scale is not the most appropriate tool for assessing respiratory impairment in myasthenia gravis
Danish and French clinicians investigated the diagnostic and predictive value of the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale for respiratory function in patients with myasthenia gravis: 70 adults with a confirmed diagnosis of myasthenia gravis took part in the study, which involved completing three functional scales (the MGC, the QMG, and the MG-ADL) … [Read more]
Sexual dysfunction remains understudied in neuromuscular disorders
A team from the Institute of Myology conducted a literature review to assess the current state of knowledge regarding sexual dysfunction in neuromuscular diseases. The analysis covered 27 studies conducted between 1983 and 2024, involving 2,428 patients. Sexual dysfunction is common and varied in neuromuscular diseases, with multifactorial mechanisms (endocrine, neuromuscular, psychological or related to … [Read more]
Is there an increased risk of cancer in autoimmune myasthenia gravis?
Israeli researchers have investigated the risk of developing cancers other than thymoma in patients with autoimmune myasthenia gravis: data on 1,558 adults with myasthenia gravis were extracted from the Israeli Clalit health database, then compiled and compared with those of a control group; this group of patients had a higher rate of cancers (leukaemia or … [Read more]
The real-world effects of medications contraindicated in Myasthenia Gravis
French clinicians have examined the links between autoimmune myasthenia gravis and medications that are traditionally contraindicated (either formally or relatively) for this condition: The National Health Data System (SNDS) was used to conduct a study tracking potential complications associated with these medications over the 2013–2020 period; data from 14,459 people with autoimmune myasthenia gravis were … [Read more]
An increased risk of urinary disorders in cases of autoimmune myasthenia
In order to study immune disorders in autoimmune myasthenia gravis, a recent study compared 86 patients with the disease and 90 hospitalized controls, matched for age and gender and assessed using the ICIQ-UI SF (urinary incontinence) and OABSS (overactive bladder) questionnaires. The prevalence of urinary incontinence was significantly higher in patients with autoimmune myasthenia gravis … [Read more]
A case of Lambert-Eaton syndrome successfully treated with efgartigimod
Chinese clinicians report the case of a 73-year-old patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS) who underwent treatment with a latest-generation immunosuppressant: the patient met all the criteria necessary to confirm the diagnosis of LEMS, including the onset of motor disorders in the context of small cell lung cancer, a compatible electrophysiological study and positive … [Read more]
Is rituximab useful in ocular myasthenia gravis?
Chinese clinicians report encouraging results regarding the use of rituximab, an anti-CD20 monoclonal antibody, in forms of ocular myasthenia gravis: their pilot study involved 9 adult patients treated between 2023 and 2024 with a low dose of rituximab (200 mg), all of whom were seropositive for acetylcholine receptor (AChR) antibodies, the treatment led to a … [Read more]
Promising results from a CAR-T cell trial in refractory myasthenia gravis
Following the publication of initial success in 2024, a Chinese team has published the results of a multicentre phase I trial that evaluated three different doses of autologous anti-BCMA and anti-CD19 CAR-T cells preceded by lymphodepletion in 18 adults with refractory autoimmune myasthenia gravis: myasthenia had previously been resistant to IV immunoglobulins (67% of participants), … [Read more]
A thymectomy before the generalisation of myasthenia would be preferable in certain patients
While there is still no consensus on the treatment of ocular myasthenia gravis, an Italian team conducted a retrospective study of 174 patients initially diagnosed with an ocular form of myasthenia gravis: 112 underwent thymectomy at the ocular stage of myasthenia gravis, 62 at the generalised stage; 29.3% had thymoma; the stable complete remission rate … [Read more]
An original mode of administration in the treatment of refractory myasthenia gravis
An international consortium of clinicians reports the results of a phase III open-label trial designed to assess the benefit and tolerability of a monoclonal antibody, rozanolixizumab, administered by the patient either by manual pressure or via an infusion pump: 62 adults with generalised myasthenia gravis participated in the trial and were divided into two groups, … [Read more]
